| Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥ 50%) non–small cell lung cancer and a poor performance status JV Alessi, B Ricciuti, E Jiménez-Aguilar, F Hong, Z Wei, M Nishino, ... Journal for immunotherapy of cancer 8 (2), 2020 | 49 | 2020 |
| Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers Y Kobayashi, C Chhoeu, J Li, KS Price, LA Kiedrowski, JL Hutchins, ... Nature 603 (7900), 335-342, 2022 | 29 | 2022 |
| Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial AS Mansfield, Z Wei, R Mehra, AT Shaw, CH Lieu, PM Forde, AE Drilon, ... NPJ Precision Oncology 6 (1), 13, 2022 | 19 | 2022 |
| Combination of type i and type ii met tyrosine kinase inhibitors as therapeutic approach to prevent resistance M Bahcall, CP Paweletz, Y Kuang, LJ Taus, T Sim, ND Kim, KH Dholakia, ... Molecular cancer therapeutics 21 (2), 322-335, 2022 | 11 | 2022 |
| OAB-052: Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the … P Kapoor, T Schmidt, S Jacobus, Z Wei, R Fonseca, NS Callander, ... Clinical Lymphoma Myeloma and Leukemia 21, S33-S34, 2021 | 11 | 2021 |
| MA14. 04 sexual health assessment in women with lung cancer (SHAWL) study N Duma, R Acharya, Z Wei, L Seaborne, C Heisler, MJ Fidler, I Elkins, ... Journal of Thoracic Oncology 17 (9), S93-S94, 2022 | 7 | 2022 |
| Sexual dysfunction in women with lung cancer: Updates from the SHAWL study. N Florez, L Kiel, K Meza, Z Wei, E Mazzola, AI Velazquez Manana, ... Journal of Clinical Oncology 41 (16_suppl), 9071-9071, 2023 | 4 | 2023 |
| Ipatasertib in Patients with Tumors with AKT Mutations: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K K Kalinsky, W Zihan, C McCourt, EP Mitchell, JJ Wright, LA Doyle, ... European Journal of Cancer 174, S8-S9, 2022 | 4 | 2022 |
| Phase II study of erdafitinib in patients with tumors with fibroblast growth factor receptor mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131 … J Gong, AC Mita, Z Wei, HH Cheng, EP Mitchell, JJ Wright, SP Ivy, ... JCO Precision Oncology 8, e2300407, 2024 | 3 | 2024 |
| Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1 J Gong, AC Mita, Z Wei, HH Cheng, EP Mitchell, JJ Wright, SP Ivy, ... JCO Precision Oncology 8, e2300406, 2024 | 2 | 2024 |
| Sexual Health Assessment in Women with Lung Cancer study: Sexual health assessment in women with lung cancer N Florez, L Kiel, K Meza, Z Wei, E Mazzola, AI Velazquez, I Franco, ... Cancer 130 (3), 375-384, 2024 | 2 | 2024 |
| Where is your lactation room? Lactation policies and practices in oncology trainee and early career physicians. SJ Malapati, SRK Singh, D Idossa, X Jordan Bruno, F Chino, MA Patel, ... Journal of Clinical Oncology 40 (16_suppl), 11054-11054, 2022 | 2 | 2022 |
| Abstract LBA003: Erdafitinib in patients with tumors harboring FGFR gene mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub … AC Mita, Z Wei, IA Mayer, H Cheng, EP Mitchell, JJ Wright, P Ivy, RJ Gray, ... Molecular Cancer Therapeutics 20 (12_Supplement), LBA003-LBA003, 2021 | 2 | 2021 |
| Parent Penalty: Parental Leave Experiences of Trainees and Early-Career Faculty in Oncology Subspecialties SJ Malapati, D Idossa, SRK Singh, Z Wei, L Kiel, F Chino, MA Patel, ... JCO Oncology Practice 19 (10), 899-906, 2023 | 1 | 2023 |
| Tumor Volume Nadir in Patients With ALK-Rearranged Non–Small-Cell Lung Cancer Treated With Alectinib M Nishino, Z Wei, E Mazzola, T Hino, SC Tseng, ME Sanchez, H Hatabu, ... JCO Precision Oncology 7, e2200603, 2023 | 1 | 2023 |
| The parent penalty: Parental leave and return to work in trainees and early-career faculty in oncology. SJ Malapati, SRK Singh, D Idossa, X Jordan Bruno, F Chino, MA Patel, ... Journal of Clinical Oncology 40 (16_suppl), 11005-11005, 2022 | 1 | 2022 |
| Distinct genomic and immunophenotypic features of solid-predominant versus nonsolid-predominant stage I lung adenocarcinomas and association with disease recurrence after … JVM Alessi, Z Wei, B Ricciuti, VR Vaz, APC Barrichello, G Lamberti, ... Journal of Clinical Oncology 40 (16_suppl), 8514-8514, 2022 | 1 | 2022 |
| ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended for … S Kumar, Z Wei, MA Thompson, B Snyder, M Weiss, LI Wagner, ... Journal of Clinical Oncology 39 (15_suppl), TPS8052-TPS8052, 2021 | 1 | 2021 |
| Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 … N Coleman, Z Wei, DS Hong, EP Mitchell, JA Zwiebel, E Sharon, RJ Gray, ... Journal of Clinical Oncology 41 (16_suppl), 3108-3108, 2023 | | 2023 |
| Dissecting the genomic and tumor immune microenvironment factors associated with disease recurrence in resected stage I NSCLC JV Alessi, Z Wei, B Ricciuti, J Lindsay, VR Vaz, A Barrichello, B Sharma, ... Cancer Research 82 (12_Supplement), 506-506, 2022 | | 2022 |
